Navigation Links
XTL Biopharmaceuticals Ltd. Announces $9.6 Million Private Placement to Institutional Investors
Date:10/25/2007

>

XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the development of therapeutics for the treatment of neuropathic pain and hepatitis C. XTL is developing Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for the treatment of diabetic neuropathic pain. XTL is also developing several novel pre-clinical hepatitis C small molecule inhibitors. XTL also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. XTL is publicly traded on the NASDAQ, London, and Tel-Aviv Stock Exchanges (NASDAQ: XTLB; LSE: XTL; TASE: XTL).

The offering was made only to accredited investors, as such term is defined in accordance with the Securities Act of 1933, as amended. The ordinary shares have not been registered under the Securities Act of 1933, or any state securities laws. Therefore, they may not be offered or sold in the United States absent registration under or exemption from the Securities Act of 1933 and any applicable state securities laws. This announcement is neither an offer to sell nor a solicitation of an offer to buy our ordinary shares or warrants to purchase ordinary shares.

Contact:

Ron Bentsur, Chief Executive Officer

Tel: +1-(845)-267-0707 ext. 225

Cautionary Statement

Some of the statements included in this press release, particularly those anticipating future financial performance, the delisting of our ordinary shares from the Official List of the United Kingdom Listing Authority, the clinical and business prospects for our clinical compound Bicifadine, growth and operating strategies and similar matters, may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim
'/>"/>

SOURCE XTL Biopharmaceuticals Ltd
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... Biotech Leaders to Develop Blueprint to Preserve ... Boosting Rhode Island,s Growing Biotech and Medical ... 14 Several of Rhode Island,s ... biotechnology gathered today at Brown University,s Medical ... medical innovation in Rhode Island and throughout ...
(Date:12/14/2009)... Mass., Dec. 14 Decision Resources, one ... for pharmaceutical and healthcare issues, finds that, owing ... atrial fibrillation drug market will increase more than ... billion in 2018 in the United States, France, ... ,, The new Pharmacor report entitled Atrial ...
(Date:12/11/2009)... Therapeutics, Inc., a biopharmaceutical company focused on improving ... cardiovascular and muscle disease, today announced the publication ... crucial role in the progression of amyotrophic lateral ... neuromuscular synaptic regeneration in mice. The findings, ... journal Science , reveal miR-206 as a ...
(Date:12/11/2009)... Dec. 11 Marrone Bio Innovations (MBI) ... management team. Mr. Chris Hildreth joined MBI as ... responsible for expanding all commercial aspects of the ... Dr. Kin Sing (Ray) Lam joined MBI as ... company,s development efforts in scaling its broad pipeline ...
Breaking Biology Technology:Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 2Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 3Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 4The Atrial Fibrillation Drug Market Will Increase More Than Sevenfold, from $790 Million in 2008 to $6.1 Billion in 2018 2miRagen announces discovery of key microRNA implicated in Lou Gehrig's disease 2Marrone Bio Innovations Announces Two New Executive Appointments 2Marrone Bio Innovations Announces Two New Executive Appointments 3
... Cell Biosciences, Inc., a provider of nanoproteomic analysis ... launch of the Cell Biosciences CB1000 protein analysis ... cell signaling proteins. The CB1000 establishes a new ... studying signaling pathways in limited samples, such as ...
... share improvements from automating their environmental monitoring processes using MODA-EM™ ... ... April 16, 2009 -- The Parenteral Drug Association (PDA) is ... 20-24, 2009 at Red Rock Casino and Resort. During this ...
... Israel, April 16 XTL Biopharmaceuticals Ltd. (Nasdaq: ... 2009, it received notification from The Nasdaq Stock ... (the "Panel") has determined that the Company,s American Depository ... will suspend trading in the Company,s ADRs at the opening ...
Other Biology Technology:Cell Biosciences Launches Next-Generation Protein Characterization System 2ImClone Systems and Lonza Walkersville to Discuss Paperless QC Micro at PDA Annual Meeting 2ImClone Systems and Lonza Walkersville to Discuss Paperless QC Micro at PDA Annual Meeting 3XTL Biopharmaceuticals Ltd. Receives Notification of Delisting Determination by NASDAQ Listing Qualifications Panel 2
(Date:12/14/2009)... (Dec. 14, 2009) -- Researchers at Rice University and ... nanoparticle that can be tracked in real time with ... them with a fluorescent dye and kills them with ... examples from a growing field called "theranostics" that develops ... in a single procedure. , The research is available ...
(Date:12/14/2009)... of the proteins in a species of salamander that ... similar regeneration could be induced in humans. , ... University Indianapolis and colleagues investigated over three hundred proteins ... salamander that has the unique natural ability to regenerate ... that this knowledge will contribute to a better understanding ...
(Date:12/14/2009)... 14 MODA Technology Partners, a global ... and product testing for the Pharmaceutical industry, today ... company,s third generation mobile data acquisition platform. The ... further automate their regulated manufacturing processes. ,, ... Fully-Configurable Test Methods: Each test ...
Breaking Biology News(10 mins):Tracking new cancer-killing particles with MRI 2IUPUI researchers tackle protein mechanisms behind limb regeneration 2MODA Announces Availability of Third Generation Mobile Data Acquisition Platform 2OriGene Launches 5 000 Purified Human Proteins from HEK293 Cells 13667 1Ranbaxy Receives Final Approval to Manufacture and Market Glycopyrrolate Tablets 55137 1Ranbaxy Receives Final Approval to Manufacture and Market Glycopyrrolate Tablets 55137 2CareTech to Provide Web Services to Blessing Health System 55135 1CareTech to Provide Web Services to Blessing Health System 55135 2CareTech to Provide Web Services to Blessing Health System 55135 3CareTech to Provide Web Services to Blessing Health System 55135 4
... neuroscience, Aldo Faisal and Simon Laughlin from Cambridge University investigate ... that noise effects in ion channels in the brain are ... is compromised. , Neurons in the cerebral cortex of ... 4km per mm3 by using incredibly thin axons as wires, ...
... immune system from launching an all-out fight against food. ... that serves to protect against such an inflammatory immune ... issue of the journal Cell, a publication of Cell ... protein enriched in fat cells, called STAMP2, develop acute ...
... one of the most common and distressing symptoms cancer ... difficult for health care professionals to accurately assess its ... at Chicago are studying fatigue in cancer patients undergoing ... monitor behaviors such as smoking cessation and alcohol use. ...
Other Biology News:Keeping the immune system from starting a 'food fight' 2Cancer patients monitor fatigue in real time 2
Mol wt: average mol wt12,360.96 Da by calculation...
Originally developed for the culture of Drosophila; suitable for culture of other dipteran cell lines. Powder, Insect cell culture tested...
... The LIC Duet™ GST•Tag™ Ek Adaptor encodes ... ribosome binding site (rbs), ATG translation initation ... The GST•Tag sequence has been reported to ... the solubility of its fusion partners. The ...
A cost-effective serum for general cell growth requirements. All serum is collected from calves aged 10 days old or less....
Biology Products: